These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33916604)

  • 1. Longitudinal Patterns in Antithrombotic Therapy in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention in the Non-Vitamin K Oral Anticoagulant Era: A Nationwide Population-Based Study.
    Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33916604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kwon S; Jung JH; Choi EK; Lee SW; Park J; Lee SR; Kang J; Han K; Park KW; Oh S; Lip GYH
    Korean Circ J; 2021 May; 51(5):409-422. PubMed ID: 33764010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study.
    Park J; Choi EK; Han KD; Choi YJ; Lee E; Choe W; Lee SR; Cha MJ; Lim WH; Kang J; Park KW; Oh S; Lip GYH
    PLoS One; 2019; 14(1):e0209593. PubMed ID: 30645601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study.
    Park J; Choi EK; Han KD; Choi YJ; Lee SR; Cha MJ; Kang J; Park KW; Oh S; Lip GYH
    Am J Cardiol; 2019 Jun; 123(12):1921-1926. PubMed ID: 30967291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016.
    Maura G; Billionnet C; Drouin J; Weill A; Neumann A; Pariente A
    BMJ Open; 2019 Apr; 9(4):e026645. PubMed ID: 31005934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R
    J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Talib U; Nafee T; Daaboul Y; Pahlavani S; Pitliya A; Furqan MM; Datta S; Kazmi HA; Younes A; Gibson CM
    Prog Cardiovasc Dis; 2018; 60(4-5):524-530. PubMed ID: 29397950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antithrombotic treatment in acute coronary syndrome and atrial fibrillation].
    Darius H; Görge G; Spiecker M; Schinzel H
    Herz; 2019 Feb; 44(1):29-34. PubMed ID: 30689009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cardiologists' Survey on the Use of Anticoagulants and Antiplatelets in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Those Undergoing Percutaneous Coronary Intervention in India.
    Kulkarni N; Taur S; Kaur J; Akolekar R; Es S
    Cureus; 2023 Feb; 15(2):e35220. PubMed ID: 36968941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018.
    de Veer AJWM; Bennaghmouch N; Dewilde WJM; Ten Berg JM
    Neth Heart J; 2021 Mar; 29(3):135-141. PubMed ID: 33052578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study.
    Lee SR; Choi EK; Han KD; Cha MJ; Oh S; Lip GYH
    PLoS One; 2017; 12(12):e0189495. PubMed ID: 29261716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelines-data from the POLish Atrial Fibrillation (POL-AF) Registry.
    Uziębło-Życzkowska B; Krzesiński P; Maciorowska M; Gorczyca I; Jelonek O; Wójcik M; Błaszczyk R; Kapłon-Cieślicka A; Gawałko M; Tokarek T; Rajtar-Salwa R; Bil J; Wojewódzki M; Szpotowicz A; Krzciuk M; Bednarski J; Bakuła-Ostalska E; Tomaszuk-Kazberuk A; Szyszkowska A; Wełnicki M; Mamcarz A; Wożakowska-Kapłon B
    Cardiovasc Diagn Ther; 2021 Feb; 11(1):14-27. PubMed ID: 33708474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants.
    Goette A; Vranckx P
    Eur Heart J Suppl; 2020 Sep; 22(Suppl I):I22-I31. PubMed ID: 33088231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Casamira N; García-Camarero T; Montoro-Ronsano JB; Veiga G; Del Blanco BG; De La Torre JM; Gordon B; García-Dorado D; Sambola A
    Am J Med Sci; 2019 Aug; 358(2):95-103. PubMed ID: 31176420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
    Darius H
    Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation.
    Yu HT; Yang PS; Hwang J; Ryu S; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
    Korean Circ J; 2020 Mar; 50(3):267-277. PubMed ID: 32100483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study.
    Heger LA; Danzer M; Bode C; Hortmann M; Duerschmied D; Olivier CB; Moser M
    Front Med (Lausanne); 2020; 7():414. PubMed ID: 33117822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.